Last updated: 07/17/2024 16:42:12
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics study of Single and Repeated Doses of Topical GSK1278863
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Topical GSK1278863 in Healthy Volunteers and Diabetic Patients, and Repeat Doses of GSK1278863 in Diabetic Patients for the Treatment of Diabetic Foot Ulcer
Trial description: This is a randomized, placebo-controlled, single-blind (subjects and investigators will be blinded, GSK internal personnel will not be blinded), parallel-group, two part (Part A, Part B) trial in healthy volunteers and subjects with diabetic foot ulcers. Part A is designed to evaluate single applications of GSK1278863 in one cohort of healthy volunteers (intact skin) and approximately 3 cohorts of diabetic subjects. Part B is designed to evaluate first single, and then repeat applications of GSK1278863 in diabetics, both in the clinic and by subjects at home. Part B will include approximately 3 cohorts in which the concentration of drug applied will be determined by pharmacokinetic data from Part A and earlier cohorts in Part B.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Single (Investigator)
Allocation:
Randomized
Primary outcomes:
Number of participants with adverse events (AEs) and serious adverse events (SAEs) following single dose administration (Part A)
Timeframe: Up to a maximum of 75 days (Start of study treatment through final follow up 2 [28-32 days post last dose])
Number of participants with AEs and SAEs following repeat dose administration (Part B)
Timeframe: Up to a maximum of 53 days (Start of study treatment through final follow up 2 [28-32 days post last dose])
Number of participants with clinically significant 12-lead Electrocardiograms (ECGs) measurement following single dose administrations (Part A)
Timeframe: Up to a maximum of 75 days (Start of study treatment through final follow up 2 [28-32 days post last dose])
Number of participants with clinically significant 12-lead ECG measurement following repeat dose administrations (Part B)
Timeframe: Up to a maximum of 53 days (Start of study treatment through final follow up 2 [28-32 days post last dose])
Number of participants with vital sign data outside clinical concern range following single dose administration (Part A)
Timeframe: Up to a maximum of 75 days (Start of study treatment through final follow up 2 [28-32 days post last dose])
Number of participants with vital sign data outside clinical concern range following repeat dose administration (Part B)
Timeframe: Up to a maximum of 53 days (Start of study treatment through final follow up 2 [28-32 days post last dose])
Number of participants with abnormal nurse/physician observation (Part A)
Timeframe: Up to a maximum of 75 days (Start of study treatment through final follow up 2 [28-32 days post last dose])
Number of participants with abnormal nurse/physician observation (Part B)
Timeframe: Up to a maximum of 53 days (Start of study treatment through final follow up 2 [28-32 days post last dose])
Number of participants with hematology values outside the clinical concern range (Part A)
Timeframe: Up to a maximum of 75 days (Start of study treatment through final follow up 2 [28-32 days post last dose])
Number of participants with hematology data outside the clinical concern range (Part B)
Timeframe: Up to a maximum of 53 days (Start of study treatment through final follow up 2 [28-32 days post last dose])
Number of participants with clinical chemistry values outside the clinical concern range (Part A)
Timeframe: Up to a maximum of 75 days (Start of study treatment through final follow up 2 [28-32 days post last dose])
Number of participants with clinical chemistry values outside the clinical concern range (Part B)
Timeframe: Up to a maximum of 53 days (Start of study treatment through final follow up 2 [28-32 days post last dose])
Maximum observed concentration (Cmax) of GSK1278863 (Part A)
Timeframe: Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72 hrs post-dose
Cmax of GSK1278863 (Part B)
Timeframe: Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14
Time of occurrence of Cmax (Tmax) of GSK1278863 (Part A)
Timeframe: Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72hrs post-dose
Tmax of GSK1278863 (Part B)
Timeframe: Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14
Apparent terminal elimination half-life (t1/2) of GSK1278863 (Part A)
Timeframe: Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72hrs post-dose
t1/2 of GSK1278863 (Part B)
Timeframe: Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14
Lag time before observation of drug concentrations in sampled matrix (Tlag) (Part A)
Timeframe: Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72hrs post-dose
Lag time before observation of drug concentrations in sampled matrix (Tlag) (Part B)
Timeframe: Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14
Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time [AUC(0-inf)] of GSK1278863 (Part A)
Timeframe: Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72hrs post-dose
AUC(0-inf) of GSK1278863 (Part B)
Timeframe: Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14
Area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration within a participant across all treatments [AUC(0-t)] of GSK1278863 (Part A)
Timeframe: Pre-dose and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48 and 72 hrs post-dose
AUC(0-t) of GSK1278863 (Part B)
Timeframe: Pre-dose and 2 hrs on Day 1 and 7; pre-dose, 1, 2,4, 8, 12 and 24 hrs post-dose on Day 14
Secondary outcomes:
Not applicable
Interventions:
Drug: GSK1278863
Drug: Placebo
Enrollment:
65
Observational study model:
Not applicable
Primary completion date:
2017-10-02
Time perspective:
Not applicable
Clinical publications:
Eric Olson, Kelly M. Mahar, Lisa Morgan, Christina Fillmore, Claire Holland, Lawrence Lavery. Randomized Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Topical Daprodustat in Healthy Volunteers and in Patients with Diabetic Foot Ulcers. Clin Pharmacol Drug Devel. 2019;00(0):1-14
Eric Olson, Kelly M. Mahar, Lisa Morgan, Christina Fillmore, Claire Holland, Lawrence Lavery.Randomized Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Topical Daprodustat in Healthy Volunteers and in Patients with Diabetic Foot Ulcers.Clin Pharmacol Drug Devel.2019;8(6):765-778
DOI: 10.1002/cpdd.654
PMID: 30720931
Medical condition
Wound Healing
Product
daprodustat
Collaborators
Not applicable
Study date(s)
June 2013 to February 2017
Type
Interventional
Phase
1
Participation criteria
Sex
Female & Male
Age
18 - 90 years
Accepts healthy volunteers
Yes
- Inclusion Criteria - Healthy Volunteers (Part A Cohort 1)
- Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin <=1.5xupper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
Inclusion and exclusion criteria
Inclusion criteria:
- Inclusion Criteria
- Healthy Volunteers (Part A Cohort 1)
- Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin <=1.5xupper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- [Single] corrected QT interval (QTc) < 450 millisecond (msec).
- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and electrocardiogram (ECGs). A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GlaxoSmithKline (GSK) Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. Subjects with hemoglobin (Hb) values higher than ULN the normal range should always be excluded from enrollment.
- Male or female between 18 and 90 years of age inclusive, at the time of signing the informed consent.
- A female subject is eligible to participate if she is of non-childbearing potential (postmenopausal or pre-menopausal females with a documented tubal ligation or hysterectomy). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods in the protocol.
- Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in the protocol. Inclusion Criteria – DFU Subjects must meet healthy volunteer inclusion criteria and the following
- Diagnosed with Type I or Type II diabetes mellitus.
- Glycosylated haemoglobin (HbA1c) <=12%.
- QTc < 480 msec in subjects with bundle branch block.
- Lower extremity diabetic foot ulcer of 30 to 364 days’ duration.
- DFU between 1 centimeter squared (cm ^2) and 20 cm^2 at screening.
- Presence of at least one DFU that meets all of the following criteria: (a). Ulcer has been diagnosed as a full-thickness, neuropathic DFU and is located at or distal to the malleolus (excluding ulcers between the toes but including those of the heel). (b). There is a minimum 2 cm margin between the qualifying study ulcer and any other ulcers on the specified foot. (c). Ulcer size (area) >=1 cm^2 and <=12 cm^2 (post-debridement at time of randomization). (d). Wagner Grade 1. (e). Depth <=5 millimeter (mm) with no capsule, tendon or bone exposed and no tunneling, undermining, or sinus tracts. Note: If the subject has more than one qualifying DFU, the ulcer designated as the study ulcer will be at the discretion of the Investigator. Non-study ulcers being treated during the course of the study will be treated with moist wound therapy Standard of Care (SOC) identified under this study.
- Adequate vascular perfusion of the affected limb within 30 days of screening, as defined by at least one of the following: (a) Transcutaneous oxygen partial pressure (TcPO2) >35 millimeter of mercury (mmHg). (b) Ankle-Brachial Index (ABI) >=0.6 and <=1.2, confirmed by TcPO2 >35 mmHg. (c) Toe pressure (plethysmography) >50 mmHg. (d) Doppler ultrasound (biphasic or triphasic waveforms) consistent with adequate blood flow to the affected extremity, as determined by SOC. Exclusion Criteria – Healthy Volunteers (Part A Cohort 1)
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- History of malignancy within 5 years of Screening or those with a strong family history of cancer (e.g., familial cancer disorders), with the exception of squamous cell or basal cell carcinoma of the skin that has been definitively treated.
- A history of drug or alcohol abuse, or a history of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 gram of alcohol: 12 ounces (360 mililiter [mL]) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
- A positive test for human immunodeficiency virus (HIV) antibody.
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives (whichever is longer).
- Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John’s Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GlaxoSmithKline (GSK) Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- Where participation in the study would result in donation of blood or blood products in excess of 500mL within a 56 day period.
- Pregnant females as determined by positive urine human chorionic gonadotropin test at screening or prior to dosing.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- Subject is mentally or legally incapacitated. Exclusion Criteria – DFU Subjects Healthy volunteer exclusions apply to DFU subjects in addition to the following:
- Subjects with ulcers accompanied by infected cellulitis, osteomyelitis, or clinical signs or symptoms of infection, Gangrene on any part of affected limb, Active Charcot’s foot on the study limb, Planned vascular surgery, angioplasty or thrombolysis, Ulcers involving exposure of tendon, bone, or joint capsule (It is acceptable to have ulcers extending through the dermis and into subcutaneous tissue with presence of granulation tissue), Ulcers due to non-diabetic etiology.
- Any unstable vascular syndromes (such as transient ischemic attack (TIA), cerebrovascular accident (CVA), unstable angina, acute myocardial infarction (MI) or acute coronary syndrome event (ACS) and/or any major changes (per investigator’s judgment) to related medications within 6 months prior to randomization.
- History or malignancy within 5 years of screening or those with a strong family history of cancer (e.g. familial cancer disorders), with the exception of squamous cell or basal cell carcinoma of the skin that has been definitively treated.
- Other clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic, neurological, psychiatric, immunological, gastrointestinal, hematological, or metabolic disease that is, in the opinion of the Investigator or the GSK Medical Monitor, not stabilized or may otherwise impact the results of the study.
- Patients with active treatment for retinal neovascularization (e.g., diabetic proliferative retinopathy or age related macular degeneration) within 6 months of randomization.
- Patients undergoing hemodialysis.
- History of venous thrombosis defined as deep vein thrombosis, pulmonary embolism or other venous thrombotic condition within 1 year prior to screening.
- Active peptic, duodenal, or esophageal ulcer disease or any gastrointestinal bleeding, within 1 year prior to screening.
- Subjects with a platelet count <100,000/mm^3 at screening.
- Subjects with an International Normalized Ratio (INR) >1.5 at screening.
- Subjects with a hemoglobin level above the gender-specific upper limit of normal at screening.
- Subjects with a history of non-traumatic joint inflammation (with the exception of inflammation due to osteoarthritis).
- Patients with known pulmonary hypertension.
Trial location(s)
Location
GSK Investigational Site
Castro Valley, California, United States, 94546
Status
Study Complete
Location
GSK Investigational Site
Las Vegas, Nevada, United States, 89106
Status
Study Complete
Location
GSK Investigational Site
Pinellas Park, Florida, United States, 33782
Status
Study Complete
Location
GSK Investigational Site
Providence, Rhode Island, United States, 02903
Status
Study Complete
Location
GSK Investigational Site
Washington, District of Columbia, United States, 20007
Status
Study Complete
Study documents
Study report synopsis
Available language(s): English
Protocol
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2017-10-02
Actual study completion date
2017-10-02
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website